lymphoma research
personalized oncology strategy
IDIBELL
concept of personalized oncology
Resistance
relapsed lymphoma
Europe
preclinical humanized orthotopic models
Catalan Institute of Oncology
preclinical models
clinical oncology practice
ICO Hematology Service
Orthotopic Xenograft Models Group
new research line
refractory lymphomas
Bellvitge Biomedical Research Institute
orthotopic approach
long term research position
Lourdes Farre
FIOCRUZ
PORTAL
knowledge
proposal
humanized patient derived othotopic xenografts
Hematology Department
scientific dissemination
privileged position
scientific activity
major treatment challenge
general treatment paradigm
Oswaldo Cruz Foundation
Head
Director Board
Brazil
ImmunePDOX
hematological cancers
Chemotherapy
solid multidisciplinary training program
qualitative improvement
response
Ana Sureda
collaboration
access
EuroPDX
career
leader
s spin-off Xenopat
Pharmaceuticals
maturity
policy priorities
Barcelona
public engagement activities
educational interventions
HTLV
best therapeutic option
empiric
Alberto Villanueva
mechanisms
gender issues
proof
years
independent researcher
infection
Spain
priority